×
About 73,870 results

AllMedicine All Center

Research & Reviews  33,853 results

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

Management of Rare Ovarian Cancer Histologies
https://ascopubs.org/doi/abs/10.1200/JCO.18.02419
Gershenson, D. et. al.

Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women wit...

see more →

Guidelines  147 results

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

Management of Rare Ovarian Cancer Histologies
https://ascopubs.org/doi/abs/10.1200/JCO.18.02419
Gershenson, D. et. al.

Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women wit...

see more →

Drugs  123 results see all →

Clinicaltrials.gov  36,947 results

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

Management of Rare Ovarian Cancer Histologies
https://ascopubs.org/doi/abs/10.1200/JCO.18.02419
Gershenson, D. et. al.

Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women wit...

see more →

News  2,741 results

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheri...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer - US Preventive Services Task Force Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2748515

Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...

Management of Rare Ovarian Cancer Histologies
https://ascopubs.org/doi/abs/10.1200/JCO.18.02419
Gershenson, D. et. al.

Aug 11th, 2019 - Management of Rare Ovarian Cancer Histologies. David M. Gershenson, MD1. x. David M. Gershenson.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women wit...

see more →

Patient Education  59 results see all →